Ethris Gmbh

Mondogen Gmbh

Ludwig Weiss

Carsten Rudolph

Christian Plank

Manish Kumar Aneja

Johannes Geiger

Christian Dohmen

Mehrije Ferizi

Peter Hofschneider

Peter Habenberger

Rebekka Kubisch-Dohmen

Zeljka Trepotec

Verena Mummert

Heymut Omran

Petra Pennekamp

Niki Tomas Loges

Sandra Cindric

Kai Wohlgemuth

Johanna Raidt

Adrian Ter Steege

Described are DNA molecules which can be transcribed into an mRNA harbouring novel UTR sequences combining the advantages of being extremely short and at the same time allowing for high translation efficiencies of RNA molecules containing them. Further, described are vectors comprising such a DNA molecule and to host cells comprising such a vector. Moreover, described are corresponding RNA molecules containing such UTRs. Further, described is a pharmaceutical composition comprising the described RNA molecule and optionally a pharmaceutically acceptable carrier as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.

Minimal UTR sequences

Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with a gene of the ATP-binding cassette (ABC) family, such as ABCA3.

ATP-binding cassette family coding polyribonucleotides and formulations thereof

Described are DNA molecules which can be transcribed into an mRNA harbouring novel UTR sequences combining the advantages of being extremely short and at the same time allowing for high translation efficiencies of RNA molecules containing them. Further, described are vectors comprising such a DNA molecule and to host cells comprising such a vector. Moreover, described are corresponding RNA molecules containing such UTRs. Further, described in a pharmaceutical composition comprising the described RNA molecule are optionally a pharmaceutically acceptable carrier as well as to the use of the described UTRs for translating a coding region of an RNA molecule into a polypeptide or a protein encoded by said coding region.

This invention relates to an HBV vector in which functional genes of HBV are at least partially deleted. In addition, this invention concerns a process for producing such an HBV vector as well as cells usable for this purpose.

HBV vectors and cells for producing the same

Growing community of inventors

Kissing, Germany

Ludwig Weiss